Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin.
Matsumura
Y
Y
Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo, Japan. yumatsu@crest.ocn.ne.jp
Hori
T
T
Nishigori
C
C
Shirogane
K
K
Toda
K-I
KI
Uchiyama
T
T
Tanaka
Y
Y
Miyachi
Y
Y
D000328:Adult; D000368:Aged; D000954:Antigens, Surface; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007375:Interleukin-1 / Q000494:pharmacology; D008024:Ligands; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D011565:Psoriasis / Q000276:immunology* / Q000473:pathology; D053262:Receptors, OX40; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins / Q000494:pharmacology; D012867:Skin / Q000276:immunology / Q000473:pathology; D018417:Th1 Cells / Q000276:immunology; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism* / Q000494:pharmacology
D000954:Antigens, Surface; D007375:Interleukin-1; D008024:Ligands; D008565:Membrane Proteins; D053262:Receptors, OX40; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; C505716:TNFRSF4 protein, human; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D014409:Tumor Necrosis Factor-alpha